权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Exploration of SF3 as a Chemical Probe for Chlamydial Biology

SF3 作为衣原体生物学化学探针的探索

基本信息

批准号：
10043281
负责人：
HUIZHOU FAN
金额：
$ 19.52万
依托单位：
RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-01 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10043281
关键词：
Affect Age Antibiotic Resistance Antibiotics Bacteria Bacterial Infections Binding Biology Calorimetry Case Study Catalytic Domain Cells Characteristics Chemicals Chlamydia Chlamydia Infections Chlamydia trachomatis Circular Dichroism Clinical Treatment Communities DNA DNA-Directed RNA Polymerase Defect Development Dissociation Ectopic Pregnancy Environment Exhibits Genes Genetic Transcription Glycine Goals Grant Growth Growth and Development function Holoenzymes In Vitro Infection Infertility Interferometry Knowledge Lactobacillus Lead Mediating Medical Microbiology Molecular Molecular Conformation Mutation Pelvic Inflammatory Disease Prevention Preventive Promoter Regions Proteins RNA RNA chemical synthesis Research Resistance Risk Role Scientist Sexual Transmission Sigma Factor Structure Testing Therapeutic Titrations Transcriptional Activation Transcriptional Regulation Treatment Failure Vaccines Variant Woman abortion antimicrobial biophysical chemistry cell growth disorder prevention extracellular in vivo inhibitor/antagonist microbiota mutant negative affect novel novel therapeutics overexpression pathogen pathogenic bacteria prevent reproductive structural biology transcription factor transcriptomics vaginal microbiota

项目摘要

PROJECT SUMMARY/ABSTRACT This R21 grant explores the utilities of a novel chemical probe termed SF3, which belongs to a group of compounds termed selective antichlamydial benzal acylhydrazones (SACBAHs). Chlamydia trachomatis is the number one sexually transmitted bacterial pathogen, which accounts for 60% of the total infected cases reported to the Centers for Diseases and Prevention. Common complications from C. trachomatis infection include infertility, abortion, ectopic pregnancy and pelvic inflammatory syndrome. Unfortunately, an effective vaccine has yet to be developed despite numerous efforts by the scientific community over half of a century. Although several broad-spectrum antibiotics can be used to treat the infection, they negatively affect the beneficial microbiota, and may increases the risk of antibiotic resistance in unrelated pathogens. In addition, clinical treatment failure with current therapies is common. There is a clear need to develop selective inhibitors and investigate their mechanisms for treatment and prevention of chlamydial infection. Our research group has identified SACBAHs as novel antichlamydials. SACBAHs exhibit several important characteristics. First, they are effective against chlamydial growth. Second; they do not affect host cell growth at concentrations that show complete inhibition of chlamydial growth. Third, they do not affect the growth of beneficial lactobacilli, which dominate the vaginal microbiota in most reproductive-age women. Our preliminary studies suggest that SACBAHs inhibit chlamydiae by interfering with the function of the Chlamydia-specific transcription factor GrgA. We will determine how SF3 affects chlamydial transcription at both the cellular and molecular levels.

项目总结/文摘